

DAFTAR PUSTAKA

- Abe M, Maruyama N, Okada K, Matsumoto S, Matsumoto K, Soma M. 2011. *Effects of Lipid-Lowering Therapy with Rosuvastatin on Kidney Function and Oxidative Stress in Patients with Diabetic Nephropathy*. Journal of Atherosclerosis and Trombosis; 18(11): 1018-1028
- Afsar B, Turkmen K, Coviv A, Kanbay M. 2014. *An Update on Coronary Artery Disease and Chronic Kidney Disease*. International Journal of Nephrology. DOI: <http://dx.doi.org/10.1155/2014/767424>
- Arora. Pradeep. 2019. *Chronic Kidney Disease*. Medscape. Tersedia pada <https://emedicine.medscape.com/article/238798-print>
- Baltatzi M, Savopulos Ch, Hatzitolios A. 2011. *Role of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in hypertension of chronic kidney disease and renoprotection*. Hipokratia; 15(1): 27-32
- Daenen K, Andries A, Mekahli D, Schepdael AV, Jouret F, Bammens B. 2017. *Oxidative Stress in Chronic Kidney Disease*. Springer. Pediatric Nephrology. Tersedia pada: <https://doi.org/10.1007/s00467-018-4005-4>
- Divisions of Nephrology & Hypertension and General Internal Medicine. 2011. *Chronic Kidney Disease: Clinical Practice Recommendations for Primary Care Physicians and Healthcare Providers, edition 6.0*. Henry Ford Health System
- Duni A, Liakopoulos V, Rapsomanikis KP, Dounousi E. 2017. *Chronic Kidney Disease and Disproportionally Increased Cardiovascular Damage: Does Oxidative Stress Explain the Burden?*. Hindawi. DOI: <https://doi.org/10.1155/2017/9036450>
- Eugenio-Perez D, Medina-Fernandez LY, Saldivar-Anaya JA, Molina-Jijon E, Pedraza-Chaverri J. 2016. *Role of Dietary Antioxidant Agents in Chronic Kidney Disease*. IntechOpen; 18: 363-381.
- Fasset RG, Robertson IK, Ball MJ, Geraghty DP, Coombes JS. 2015. *Effects of atorvastatin on oxidative stress in chronic kidney disease*. Nephrology; 20: 697-705
- Francisqueti FV, Chiaverini LCT, Santos KCd, Minatel IO, Ronchi CB, Ferron AJT, Ferreira ALA, Correa CR. 2016. *The role of oxidative stress on the pathophysiology of metabolic syndrome*. Rev Assoc Med Bras 2017; 63(1):85-91. Tersedia pada: <http://dx.doi.org/10.1590/1806-9282.63.01.85>
- Gamboa JL, Pretorius M, Todd-Tzanetos DR, Luther JM, Yu Chang, Ikizler TA, Brown NJ. 2012. *Comparative Effects of Angiotensin-Converting Enzyme Inhibition and Angiotensin-Receptor Blockade on Inflammation during Hemodialysis*. J Am Soc Nephrol; 23: 334-342.
- Gonzales J, Valls N, Brito R, Rodrigo R. 2014. *Essential hypertension and oxidative stress: New insights*. World J Cardiol 2014; 6(6): 353-366. Tersedia pada: <http://dx.doi.org/10.4330/wjc.v6.i6.353>

- He J, Shlipak M, Anderson A, Roy JA, Feldman HI, Kallem RR, Kanthety R, Kusek JW, Ojo A, Rahman M, Ricardo AC, Soliman EZ, Wolf M, Zhang X, Raj D, Hamm L. 2017. *Risk Factors for Heart Failure in Patients with Chronic Kidney Disease: The CRIC (Chronic Renal Insufficiency Cohort) Study*. J Am Heart Assoc; 6: e005336
- Hill NR, Fatoba ST, Oke JL, Hirst JA, O'Callaghan CA, Lasserson DS, Hobbs FDR. 2016. *Global Prevalence of Chronic Kidney Disease – A Systematic Review and Meta-Analysis*. PLOS ONE. DOI: 10.1371/journal.pone.0158765
- Hsu TW, Liu JS, Hung SC, Kuo KL, Chang YK, Chen YC, Hsu CC, Tarng DC. 2014. *Renoprotective Effect of Renin-Angiotensin-Aldosterone System Blockade in Patients with Predialysis Advanced Chronic Kidney Disease, Hypertension, and Anemia*. JAMA Intern Med; 174(3): 347-354
- Ho, E. *et al.* 2013. *Biological markers of oxidative stress: Applications to cardiovascular research and practice*. Elsevier. Redox Biology; 1(1): 483–491. DOI: 10.1016/j.redox.2013.07.006
- Iglesias P, Selgas R, Romero S, Díez JJ. 2013. *Selenium and kidney disease*. J Nephrol; 26(2): 266-272. DOI:10.5301/jn.5000213
- Indonesian Renal Registry. 2017. *10th Report of Indonesian Renal Registry*. Perkumpulan Nefrologi Indonesia (PERNEFRI)
- Institute for Health Metrics and Evaluation. 2017. *Global Burden of Disease*. University of Washington. Tersedia pada: <https://vizhub.healthdata.org/gbd-compare/>
- Jouyban A dan Khoubnasabjafari M. 2017. *Is Malondialdehyde an Acceptable Biomarker of Oxidative Stress In Children with Down Syndrome?*. Iran J Pediatr 2017; 27(5): e6892. DOI: 10.5812/ijp.6892. Tersedia pada: <http://ijp.tums.pub/en/articles/6892.html>
- Jonathan, Himmelfarb dan Sayegh Mohamed H. 2010. *Chronic Kidney Disease, Dialysis, and Transplantation E-Book*. Elsevier Health Science.
- Judd E dan Calhoun DA. 2015. *Management of Hypertension in CKD: Beyond the Guidelines*. Adv Chronic Kidney Dis. March 2015; 22(2): 116–122. DOI: 10.1053/j.ackd.2014.12.001
- Kalaitzidis RG dan Elisaf MS. 2018. *Treatment of Hypertension in Chronic Kidney Disease*. Springer. Current Hypertension Reports (2018) 20: 64. Tersedia pada: <https://doi.org/10.1007/s11906-018-0864-0>
- Kayabasi H, Yilmaz Z, Sit D, Kadigroglu AK, Yilmaz E. 2013. *The effects of Losartan on oxidative stress and inflammation in non-diabetic patients undergoing chronic hemodialysis*. European Review for Medical and Pharmacological Science; 12: 235-242
- Kemenkes RI. 2018. “Cegah Dan Kendalikan Penyakit Ginjal Dengan Cerdik Dan Patuh”. Kementrian Kesehatan Republik Indonesia. Tersedia pada:

<http://www.depkes.go.id/article/print/18030700007/cegah-dan-kendalikan-penyakit-ginjal-dengan-cerdik-dan-patuh.html>

- Kemenkes RI. 2017. *Situasi Penyakit Ginjal Kronis*. Jakarta: Pusat Data dan Informasi Kementerian Kesehatan RI
- Khoubnasabjafari M, Ansarin K, Jouyban A. 2015. *Reliability of malondialdehyde as a biomarker of oxidative stress in psychological disorders*. *BioImpacts* 2015; 5(3); 123-127. DOI: 10.15171/bi.2015.20. Tersedia pada: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4597159/>
- Kidney Disease Improving Global Outcomes. 2012. *KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease*. International Society of Nephrology 2013; 3, Issue 1. Tersedia pada: <http://www.kidney-international.org>
- Kolesnyk I, Struijk DG, Dekker FW, Krediet RT. 2010. *Effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with chronic kidney disease*. *The Journal Medicine*; 68(1): 15-23
- Krata N, Zagodzón R, Foronczewicz B, Mucha K. *Oxidative Stress in Kidney Diseases: The Cause or the Consequence?*. Springer. *Archivum Immunologiae et Therapiae Experimentalis* 2018; 66:211–220. Tersedia pada: <https://doi.org/10.1007/s00005-017-0496-0>
- Ku E, McCulloch CE, Vittinghoff E, Lin F, Johansen KL. 2018. *Use of Antihypertensive Agents and Association with Risk of Adverse Outcomes in Chronic Kidney Disease: Focus on Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers*. *J Am Heart Assoc*; 7: e009992
- Law MR, Wald NJ, Morris JK, Jordan RE. 2003. *Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials*. *BMJ*; 326: 1427–1431
- Leonberg-Yoo AK dan Rudnick MR. 2017. *Tobacco Use: A chronic Kidney Disease Accelerant*. *Am J Nephrol*; 46: 257–259
- Li Robert, Jia Z, Trush MA. 2016. *Defining ROS in Biology and Medicine*. HHS Public Access. *React Oxyg Species (Apex)* 2016; 1(1): 9–21. DOI: 10.20455/ros.2016.803. Tersedia pada: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5921829/>
- Liakopoulos, V. Roumeliotis S, Bozikas A, Eleftheriadis T, Dounousi E. 2019. *Antioxidant Supplementation in Renal Replacement Therapy Patients: Is There Evidence?*. Hindawi. DOI: <https://doi.org/10.1155/2019/9109473>
- Lima EG, Batista DV, Martins EB, Hueb W. 2018. *Chronic Kidney Disease and Coronary Artery Disease*. *Advances in Nephropathy*: 9
- Ling, Xiao Chun dan Kuo, Ko-Lin. 2018. *Oxidative Stress in Chronic Kidney Disease*. Tersedia pada: <https://doi.org/10.1186/s41100-018-0195-2>

- Luyckx VA, Tonelli M, Stanifer JW. 2018. *The global burden of kidney disease and the sustainable development goals*. Bulletin of the World Health Organization 2018;96:414-422D. DOI: <http://dx.doi.org/10.2471/BLT.17.206441>. Tersedia pada: <https://www.who.int/bulletin/volumes/96/6/17-206441/en/>
- Major RW, Cheng MRI, Grant RA, Shantikumar S, Xu G, Oozeerally I, Brunskill NJ, Gray LJ. 2018. *Cardiovascular disease risk factors in chronic kidney disease: A systematic review and metaanalysis*. PLOS ONE 13(3): e0192895. DOI: <https://doi.org/10.1371/journal.pone.0192895>
- Matovinović, MS. 2009. *Pathophysiology and Classification of Kidney Diseases*. eJIFCC 2009; 20/01. Tersedia pada: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4975264/>
- Mikrut K, Kupsz J, Kozlik J, Krauss H, Proszynska-Oszmalek E, Gibas-Dorna M. 2016. *Angiotensin-converting enzyme inhibitors reduce oxidative stress intensity in hyperglycemic conditions in rats independently from bradykinin receptor inhibitors*. Croat Med J; 57: 371-380
- Minas JN, Thorwald MA, Conte D, Medina-Varquez JP, Nishiyama A, Ortiz RM. 2015. *Angiotensin and Mineralocorticoid Receptor Antagonism Attenuates Cardiac Oxidative Stress in Angiotensin II-Infused Rats*. Clin Exp Pharmacol Physiol; 42(11): 1178–1188
- Moderasi A, Nafar M, Sahrein Z. 2015. *Oxidative Stress in Chronic Kidney Disease*. Iranian Journal of Kidney Diseases. IJKD 2015; 9:165-79
- Molnar MZ, Zadeh KK, Lott EH, Lu JL, Malakauskas SM, Ma JZ, Quarles DL, Kovesdy CP. 2014. *ACE Inhibitor and Angiotensin Receptor Blocker Use and Mortality in Patients with Chronic Kidney Disease*. Am Coll Cardiol; 63(7): 650–658
- Moreto F, de Oliveira EP, Manda RM, Burini RC. 2014. *The Higher Plasma Malondialdehyde Concentrations Are Determined by Metabolic Syndrome-Related Glucolipotoxicity*. Hindawi Publishing Corporation. Oxidative Medicine and Cellular Longevity 2014. DOI: <http://dx.doi.org/10.1155/2014/505368>
- Nakamura A, Shikata K, Nakatou T, Kitamura T, Kajitani N, Ogawa D, Makino H. 2013. *Combination therapy with an angiotensin-converting-enzyme inhibitor and an angiotensin II receptor antagonist ameliorates microinflammation and oxidative stress in patients with diabetic nephropathy*. Journal of Diabetes Investigation; 4(2): 195-201
- National Clinical Guideline Centre. 2014. *Chronic kidney disease (partial update): Early identification and management of chronic kidney disease in adults in primary and secondary care*. National Institute for Health and Care Excellence

- National Kidney Foundation. 2013. *KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease*. Kidney International Supplement, 3(1)
- National Kidney Foundation. *K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease*.
- National Health Service. 2016. “Chronic Kidney Disease”. United Kingdom: National Health Service. Tersedia pada: <https://www.nhs.uk/conditions/kidney-disease/>
- National Health Service. 2019. “High blood pressure (hypertension)”. United Kingdom: National Health Service. Tersedia pada: <https://www.nhs.uk/conditions/high-blood-pressure-hypertension/treatment/>
- National Institute of Health. 2016. “Chronic Kidney Disease”. United States: National Institute of Diabetic and Digestive and Kidney Disease. Tersedia pada: <https://www.niddk.nih.gov/health-information/kidney-disease/chronic-kidney-disease-ckd>
- Neugarten J, Golestaneh L, *Gender and the prevalence and progression of renal disease*. Adv Chronic Kidney Dis. 2013; 20(5): 390-395.
- Nuhu F. dan Bhandari S. 2018. *Oxidative Stress and Cardiovascular Complications in Chronic Kidney Disease, the Impact of Anaemia*. Pharmaceuticals, 11, 103. DOI: 10.3390/ph11040103
- Ojo, Akinlolu. 2014. *Addressing the Global Burden of Chronic Kidney Disease Through Clinical and Translational Research*. Transactions of the American Clinical and Climatological Association, 125, 229-43; discussion 243-6. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4112688/>
- Pesta D and Roden M. 2017. *The Janus Head of Oxidative Stress in Metabolic Diseases and During Physical Exercise*. Springer. Curr Diab Rep 2017; 17: 41. DOI: 10.1007/s11892-017-0867-2. Tersedia pada: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5403850/>
- Putri AY dan Thaha M. 2014. *Role of Oxidative Stress on Chronic Kidney Disease Progression*. Acta Medica Indonesiana. The Indonesian Journal of Internal Medicine 2014; 46: 3. Tersedia pada: <http://www.inaactamedica.org/archives/2014/25348188.pdf>
- Ramalingam L, Menikdiwela K, LeMieux M, Dufour JM, Kaur G, Kaluphanna N, Moussa NM. 2016. *The Renin Angiotensin System, Oxidative Stress and Mitochondrial Function in Obesity and Insulin Resistance*. Elsevier. Tersedia pada: <http://dx.doi.org/10.1016/j.bbadis.2016.07.019>
- Ravarotto V, Simioni F, Pagnin E, Davis PA, Calo LA. 2018. *Oxidative stress – chronic kidney disease – cardiovascular disease: A vicious circle*. Elsevier. Life Sciences 2018; 210: 125–131. Tersedia pada: <https://doi.org/10.1016/j.lfs.2018.08.067>

- Renal Association. 2019. "The UK eCKD Guide: Hypertension". United Kingdom: The Renal Association
- Rodrigo R, Gonzáles J, Paoletto F. 2011. *The role of oxidative stress in the pathophysiology of Hypertension*. Hypertension Research; 34: 431-440
- Roumeliotis S, Roumeliotis A, Dounousi E, Eleftheriadis T, Liakopoulos V. 2019. *Dietary Antioxidant Supplements and Uric Acid in Chronic Kidney Disease: A Review*. Nutrients; 11(1911)
- Sabe MA, Claggett B, Burdmann EA, Desai AS, Ivanovich P, Kewalramani R, Lewis EF, McMurray JJV, Olson KA, Parfrey P, Solomon SD, Pfeffer MA. 2016. *Coronary Artery Disease Is a Predictor of Progression to Dialysis in Patients with Chronic Kidney Disease, Type 2 Diabetes Mellitus, and Anemia: An Analysis of the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT)*. J Am Heart Assoc; 5: e002850
- Sahni, Nancy dan Gupta Krishan L. 2012. *Dietary antioxidants and oxidative stress in predialysis chronic kidney disease patients*. Journal of Nephropatology; 1(3): 134-142
- Salehi M, Sohrabi Z, Ekramzadeh M, Fallahzadeh MK, Ayatollahi M, Geramizadeh B, Hassanzadeh J, Sagheb MM. 2013. *Selenium supplementation improves the nutritional status of hemodialysis patients: a randomized, double-blind, placebocontrolled trial*. Nephrol Dial Transplant; 28: 716–723
- Samak MJ, Amann K, Bangalore S, Cavalcante JL, Charytan DM, Craig JC, Gill JS, Hlatky MA, Jardine AG, Landmesser U, Newby K, Herzog CA, Cheung M, Wheeler DC, Winkerlamyer WC, Marwick TH. 2019. *Chronic Kidney Disease and Coronary Artery Disease*. Journal of The American College of Cardiology; 74 (14): 1823-1838
- Schieber M dan Chandel NS. *ROS Function in Redox Signaling and Oxidative Stress*. Elsevier. Curr Biol. 2014 May 19; 24(10): R453–R462. DOI: 10.1016/j.cub.2014.03.034. Tersedia pada: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4055301/>
- Schlondorff, DO. 2008. *Overview of factors contributing to the pathophysiology of progressive renal disease*. Kidney International, 2008; 74: 860–866. Tersedia pada: <https://doi.org/10.1038/ki.2008.351>
- Segall L, Nistor I, Covic A. 2014. *Heart Failure in Patients with Chronic Kidney Disease: A Systematic Integrative Review*. BioMed Research International. DOI: <http://dx.doi.org/10.1155/2014/937398>
- Sinha AD dan Agarwal R. 2019. *Clinical Pharmacology of Antihypertensive Therapy for the Treatment of Hypertension in Chronic Kidney Disease*. The American Society of Nephrology. Clin J Am Soc Nephrol 14. Tersedia pada: <https://doi.org/10.2215/CJN.04330418>
- Siswanto. 2016. "Menjaga Ginjal Tetap Sehat". Kementerian Kesehatan Republik Indonesia. Tersedia pada:

<http://www.depkes.go.id/development/site/depkes/index.php?cid=1-16100600002&id=memelihara-ginjal-tetap-sehat.html>

- Sulistiowati E dan Idaiani S. 2015. *Faktor Risiko Penyakit Ginjal Kronis Berdasarkan Analisis Cross-sectional Data Awal Studi Kohort Penyakit Tidak Menular Penduduk Usia 25-65 Tahun di Kelurahan Kebon Kalapa, Kota Bogor Tahun 2011*. Pusat Teknologi Terapan Kesehatan dan Epidemiologi Klinik. Buletin Penelitian Kesehatan September 2015; 43: 163-172
- Sung, C. *et al.* 2013. *Oxidative Stress and Nucleic Acid Oxidation in Patients with Chronic Kidney Disease*. *Oxidative Medicine and Cellular Longevity* 2013; 1-15. Tersedia pada: <http://dx.doi.org/10.1155/2013/301982>
- Thaha M, Kadariswantiningsih IN, Empitu MA. 2019. *Association of High Blood Pressure with Elevated Oxidative Stress, Inflammatory Marker and Albuminuria in Chronic Kidney Disease Patients*. *J MEDICINE* 2019; 20: 12-18. DOI: <http://dx.doi.org/10.3329/jom.v20i1.38815>
- The Australian Kidney Foundation. 2015. *Chronic Kidney Disease (CKD) Management in General Practice 3rd Edition*. The Australian Kidney Foundation ABN 37 008 464 426. American Society of Nephrology. *Clin J Am Soc Nephrol* 2014; 14. Tersedia pada: <https://doi.org/10.2215/CJN.04330418>
- The National Kidney Foundation. 2015. “*Global Facts: About Kidney Disease*”. New York: National Kidney Foundation. Tersedia pada: <https://www.kidney.org/kidneydisease/global-facts-about-kidney-disease>
- Tibaut M dan Petrovic D. 2016. *Oxidative Stress Genes, Antioxidants and Coronary Artery Disease in Type 2 Diabetes Mellitus*. *Cardiovascular & Hematological Agents in Medicinal Chemistry*; 14: 23-38
- Trevor AJ, Katzung BG, Kruidering-Hall M. 2015. *Katzung’s & Trevor’s Pharmacology: Examination & Broad Review*, 11th edition. LANGE
- To’oli C, Carvalho AB, Ammirati AL, Draibe SA, Canziani MEF (2019) Associated factors related to chronic kidney disease progression in elderly patients. *PLoS ONE* 14(7): e0219956.
- Weinstein JR dan Anderson S. 2010. *The Aging Kidney: Physiological Changes*. *Adv Chronic Kidney Dis*; 17(4): 302–307
- Wong, Eric. 2012. “Chronic Kidney Disease (CKD)”. *McMaster Pathophysiology Review*. Tersedia pada <http://www.pathophys.org/ckd/>
- World Kidney Day. “*Chronic Kidney Disease*”. Belgia: World Kidney Day. Tersedia pada: <https://www.worldkidneyday.org/faqs/chronic-kidney-disease/>
- Yacoub R, Habib H, Lahdo A, Ali RA, Varjabedian L, Atalia G, Aki NK, Aldakheel S, Alahdab S, Albitar S. 2010. *Association between smoking and chronic kidney disease: a case control study*. *BMC Public Health*, 10: 731

- Zachara, Bronislaw A. 2015. *Chapter Five - Selenium and Selenium-Dependent Antioxidants in Chronic Kidney Disease*. *Advances in Clinical Chemistry*; 68: 131-151.
- Zheng C, Wang JY, Chen TT, Wu YC, Wu YL, Lin HT, PoChiu S, Chang TJ, Zheng JQ, Chu NF, Lin YM, Su SL, Lu KC, Chen JS, Sung FC, Lee CT, Yang Y, Hwang SJ, Wang MC, Hsu YH, Chiou HY, Kao S, Wu MY, Lin YF. 2019. *Angiotensin-converting enzyme inhibitors or angiotensin receptor blocker monotherapy retard deterioration of renal function in Taiwanese chronic kidney disease population*. *Scientific Reports*; 9: 2694